Merck and Schering-Plough were supposed to be reporting second-quarter earnings this morning, but they’re holding off on those announcements until the afternoon. The reason: A Norwegian researcher is going to present “an update” from a study of Vytorin — the cholesterol drug whose problems have been a big issue for both companies this year.
The study, [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment